A UK partnership between C2N Diagnostics, Cambridge Cognition and The Alzheimer's Trust is combining blood-based amyloid and phosphorylated tau measurement with digital cognitive testing and phlebotomy/MRI infrastructure to shorten an average 3.5-year diagnostic delay. The blood test reported 91–92% sensitivity and specificity in a JAMA study of more than 1,200 patients, rising to roughly 95% with a two-cutoff approach. Paired with digital cognitive assessment in Swedish primary care, detection accuracy reached 90% versus approximately 70% for standard GP assessment.
Key Points
- Blood biomarker test matched amyloid status with 91–92% accuracy
- Blood test plus digital cognition outperformed standard GP assessment, 90% versus 70%
- UK Alzheimer's diagnosis currently averages 3.5 years after symptom onset
Longevity Analysis
Amyloid-targeting therapies now approved in the UK perform best in the earliest disease stages, which converts diagnostic delay into lost treatment window rather than administrative inconvenience. Peripheral blood measurement of amyloid ratios and phosphorylated tau makes a central nervous system process readable years before clinical certainty, shifting cognitive decline from a diagnosis of exclusion to a quantifiable signal that can be tracked and acted upon. The operational element matters as much as the assay — accuracy is irrelevant without a referral pathway, phlebotomy capacity and imaging that patients can actually reach.
Original published by Longevity.Technology, by Kyle Umipig.